sellWeak cluster of 410b5-1 plan
Alexandra Balcom sold $892k of NUVL
Chief Financial Officer at Nuvalent, Inc.. 10,000 shares at an average of $89.19, traded Oct 31, 2024, filed Nov 4, 2024.
Warning score
30Value
$892k
10,000 shares
Holdings after
33,300
-23% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +23Trade size$892k at market
- +5Share of holdings soldSold 23% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-120815, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 31, 2024 | MOption exercise Class A Common Stock10b5-1 | +10,000 | $27.85 | $279k | 43,300 | Nov 4, 2024 |
| Oct 31, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -1,980 | $88.25 | $175k | 41,320 | Nov 4, 2024 |
| Oct 31, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -6,320 | $89.17 | $564k | 35,000 | Nov 4, 2024 |
| Oct 31, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -1,600 | $90.31 | $144k | 33,400 | Nov 4, 2024 |
| Oct 31, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -100 | $90.94 | $9,094 | 33,300 | Nov 4, 2024 |
| Oct 31, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 94,200 | Nov 4, 2024 |
Related signals
Other insiders at Nuvalent, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 14Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $543k 5,500 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $2.5M 25,130 shares | -23% | |
| 30Weak | Nuvalent, Inc. | Henry E. Pelish Chief Scientific Officer | $3.4M 35,104 shares | -35% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $3.0M 30,000 shares | -8% | |
| 14Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $567k 5,500 shares | -8% | |
| 14Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $567k 5,500 shares | -9% | |
| 7Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $561k 5,500 shares | -9% | |
| 18Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $1.7M 15,000 shares | -25% | |
| 38Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $721k 7,417 shares | -8% | |
| 35Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $676k 6,952 shares | -14% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.